---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057152"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:19:22.198748+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q1 2023 net loss narrows to $22.1M; YUPELRI sales up 8% to $47M

## Summary
- Q1 GAAP net loss from continuing ops $22.1M vs $40.3M; non-GAAP net loss $14.9M vs $25.2M.
- YUPELRI net sales (Viatris) $47M, +8% YoY; Theravance's 35% share $16.4M.
- $215M of $325M buyback completed; $110M remaining; on track to finish by year-end.
- CYPRESS Phase 3 study of ampreloxetine in MSA-nOH actively recruiting; enrollment expected H2 2024.
- Jim Kelly (Weiss Asset Mgmt) appointed to Board; TRELEGY milestone $50M if 2023 global sales ≥ $2.9B.

## SEC filing metadata
- accession: 0001104659-23-057152
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/0001104659-23-057152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/tm2314872d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057152
- JSON: https://secwatch.observer/filing/0001104659-23-057152.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057152.txt

## Key facts
- Earnings Releases
  Theravance Biopharma, Inc. reported the first quarter of 2023 results: revenue $10.4 million.
  - Period: the first quarter of 2023
  - Revenue: $10.4 million
  - Result: reported results
  source text: Total revenue for the first quarter of 2023 was $10.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/0001104659-23-057152-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.